drugset / Trial / NCT02858362
Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To Assess the Activity and Safety of SMT C1100 (Ezutromid) in Paediatric Male Participants with Duchenne Muscular Dystrophy (DMD).
Timeline
- Start
- 2016-06
- Primary completion
- 2018-04-11
- Completion
- 2018-09-11
Outcome
Outcome not reported
Stopped: “The study was terminated due to lack of efficacy in Cohorts 1 and 2.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ezutromid | Small molecule | 1 g | Oral |
| Subject | Ezutromid | Small molecule | 2.5 g | Oral |